---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-064432"
form_type: "8-K"
ticker: "CYTK"
cik: "0001061983"
company_name: "CYTOKINETICS INC"
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T10:37:52.321332+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cytokinetics Q1 net loss $161.4M; aficamten PDUFA extended to Dec 26, 2025

## Summary
- Net loss $161.4M ($1.36/share) vs $135.6M ($1.33/share) in Q1 2024; revenue $1.6M.
- FDA extended aficamten PDUFA date for obstructive HCM to Dec 26, 2025 due to REMS submission; no additional clinical data requested.
- MAPLE-HCM topline results expected May 2025; ACACIA-HCM enrollment completed, topline 1H 2026.
- Cash, cash equivalents, and investments ~$1.1B at Mar 31, down $132.2M from Dec 31, 2024.
- Full-year 2025 GAAP operating expense guidance maintained at $670-710M.

## SEC filing metadata
- accession: 0000950170-25-064432
- form_type: 8-K
- ticker: CYTK
- cik: 0001061983
- company_name: CYTOKINETICS INC
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061983/000095017025064432/0000950170-25-064432-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061983/000095017025064432/cytk-20250506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-064432
- JSON: https://secwatch.observer/filing/0000950170-25-064432.json
- Plain text: https://secwatch.observer/filing/0000950170-25-064432.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.